MX2022007464A - Composiciones biofarmaceuticas y metodos relacionados. - Google Patents
Composiciones biofarmaceuticas y metodos relacionados.Info
- Publication number
- MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A
- Authority
- MX
- Mexico
- Prior art keywords
- related methods
- biopharmaceutical compositions
- compositions
- biopharmaceutical
- antagonism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949696P | 2019-12-18 | 2019-12-18 | |
| US201962950595P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/064241 WO2021126657A1 (en) | 2019-12-18 | 2020-12-10 | Biopharmaceutical compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007464A true MX2022007464A (es) | 2022-06-27 |
Family
ID=74125707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007464A MX2022007464A (es) | 2019-12-18 | 2020-12-10 | Composiciones biofarmaceuticas y metodos relacionados. |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230355757A1 (en) * | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| EP4626927A1 (en) * | 2022-11-30 | 2025-10-08 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1-antibodies |
| EP4763222A1 (en) * | 2025-08-25 | 2026-06-24 | Qilu Pharmaceutical Co., Ltd. | A composition comprising apitegromab |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| ES3053874T3 (en) * | 2015-08-24 | 2026-01-27 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| EP3357508A4 (en) * | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE |
| DK3386541T3 (da) * | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| CN110049777A (zh) * | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
-
2020
- 2020-12-10 EP EP20835967.9A patent/EP4077388A1/en active Pending
- 2020-12-10 KR KR1020227024058A patent/KR20220129548A/ko not_active Ceased
- 2020-12-10 CN CN202080094093.2A patent/CN115298218A/zh active Pending
- 2020-12-10 AU AU2020407007A patent/AU2020407007A1/en not_active Abandoned
- 2020-12-10 WO PCT/US2020/064241 patent/WO2021126657A1/en not_active Ceased
- 2020-12-10 JP JP2022537240A patent/JP2023507981A/ja active Pending
- 2020-12-10 BR BR112022014694A patent/BR112022014694A2/pt not_active Application Discontinuation
- 2020-12-10 IL IL293753A patent/IL293753A/en unknown
- 2020-12-10 US US17/785,506 patent/US20230059341A1/en active Pending
- 2020-12-10 CA CA3164600A patent/CA3164600A1/en active Pending
- 2020-12-10 MX MX2022007464A patent/MX2022007464A/es unknown
-
2025
- 2025-05-23 AU AU2025203823A patent/AU2025203823A1/en active Pending
- 2025-11-04 JP JP2025185522A patent/JP2026027328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220129548A (ko) | 2022-09-23 |
| CA3164600A1 (en) | 2021-06-24 |
| IL293753A (en) | 2022-08-01 |
| AU2020407007A1 (en) | 2022-06-23 |
| JP2026027328A (ja) | 2026-02-18 |
| EP4077388A1 (en) | 2022-10-26 |
| CN115298218A (zh) | 2022-11-04 |
| WO2021126657A1 (en) | 2021-06-24 |
| JP2023507981A (ja) | 2023-02-28 |
| AU2025203823A1 (en) | 2025-06-19 |
| US20230059341A1 (en) | 2023-02-23 |
| BR112022014694A2 (pt) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004003A2 (es) | Composiciones y anticuerpos anti-lag-3 | |
| CO2018003500A2 (es) | Anticuerpos anti-pd-1 y composiciones | |
| CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| PE20211412A1 (es) | Anticuerpos anti-gdf15, composiciones y metodos de uso | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| CO2019012080A2 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 | |
| UY37957A (es) | Moduladores de la vía de estrés integrada | |
| UY37956A (es) | Moduladores de la vía de estrés integrada | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| UY37958A (es) | Moduladores de la vía de estrés integrada | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| CO2017010618A2 (es) | Anticuerpos contra icos | |
| JOP20200177A1 (ar) | طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| BR112022011629A2 (pt) | Anticorpos biespecíficos caninizados para tratar dermatite atópica | |
| UY37230A (es) | Moduladores de la vía de estrés integrada | |
| UY37231A (es) | Moduladores de la vía de estrés integrada | |
| UY37228A (es) | Moduladores de la vía de estrés integrada | |
| MX2019005277A (es) | Composiciones de celulas t con car anti-bcma. | |
| MX2017000985A (es) | Anticuerpos anti-pd-1. | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. |